Noticias de ATHE_US

Noticias del mercado

Últimas noticias sobre ATHE_US — 106 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ATHE_US ✕ 106 resultados
15/04/2026 ATHE_US — Stock Titan
No approved treatment for Multiple System Atrophy: Alterity webcast April 28
15/04/2026 ATHE_US — Yahoo Finance
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
15/04/2026 ATHE_US — The Manila Times
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
15/04/2026 ATHE_US — Stock Titan
Alterity Therapeutics (NASDAQ: ATHE) hosts KOL event on ATH434 and MSA
15/04/2026 ATHE_US — newser.com
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Shared Momentum Picks
15/04/2026 ATHE_US — Newser
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Global Trading Community
15/04/2026 ATHE_US — Newser
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Earnings Risk
15/04/2026 ATHE_US — newser.com
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - High Attention Stocks
11/04/2026 ATHE_US — Stock Titan
ATHE SEC Filings - Alterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms
10/04/2026 ATHE_US — Stock Titan
PRNAF SEC Filings - Alterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms
30/03/2026 ATHE_US — Stock Titan
Alterity Therapeutics (NASDAQ: ATHE) gets positive FDA feedback on ATH434 Phase 3 MSA program
30/03/2026 ATHE_US — Stock Titan
FDA feedback moves Alterity's atrophy drug toward Phase 3
30/03/2026 ATHE_US — Bitget
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
30/03/2026 ATHE_US — Yahoo Finance
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
30/03/2026 ATHE_US — GlobeNewswire ES ← EN
Alterity Therapeutics recibe comentarios positivos de la FDA luego de la reunión tipo C sobre el programa de fase 3 ATH434
27/03/2026 ATHE_US — The Globe and Mail
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
26/03/2026 ATHE_US — TipRanks
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
09/03/2026 ATHE_US — Stock Titan
Alterity Therapeutics (NASDAQ: ATHE) preps Phase 3 and joins Bell Potter summit
09/03/2026 ATHE_US — Stock Titan
CEO to share late-stage trial lessons at Bell Potter healthcare summit
09/03/2026 ATHE_US — Yahoo Finance
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Página 5 de 6

keyboard_arrow_up